Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 17/20 | 0.59 |
| ▸ | CDK4 | P11802 | 11/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25695039 | 0.77 | CCND1 (0.38) | CCND1CDK4CDK6 | |
| SCHEMBL29514972 | 0.77 | CCND1 (0.38) | CCND1CDK4CDK6 | |
| SCHEMBL24322143 | 0.76 | CCND1 (0.37) | CCND1CDK4CDK6 | |
| SCHEMBL25695270 | 0.75 | CCND1 (0.41) | CCND1CDK4CDK6 | |
| SCHEMBL30629568 | 0.75 | CDK4 (0.35) | CCND1CDK4CDK6 | |
| SCHEMBL30541555 | 0.73 | CCND1 (0.54) | CCND1CDK4CDK6 | |
| SCHEMBL24322989 | 0.73 | CCND1 (0.54) | CCND1CDK4CDK6 | |
| SCHEMBL25235968 | 0.72 | CCND1 (0.55) | CCND1CDK4CDK6 | |
| SCHEMBL30541535 | 0.72 | CCND1 (0.55) | CCND1CDK4CDK6 | |
| SCHEMBL30629588 | 0.71 | CCND1 (0.35) | CCND1CDK4CDK6RPS6KA5TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CCND1 46/4885CDK4 12/4885CDK6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.